MARKET

NLSPW

NLSPW

Nls Pharmaceutic
NASDAQ
0.1068
-0.0432
-28.80%
After Hours: 0.1100 +0.0032 +3.00% 16:03 01/27 EST
OPEN
0.1430
PREV CLOSE
0.1500
HIGH
0.1430
LOW
0.0999
VOLUME
317.54K
TURNOVER
0
52 WEEK HIGH
0.4800
52 WEEK LOW
0.0427
MARKET CAP
--
P/E (TTM)
-0.0953
1D
5D
1M
3M
1Y
5Y
NLS Pharmaceutics Regains Compliance With Nasdaq's Shareholders Equity Rule; Shares Rise
NLS Pharmaceutics Regains Compliance With Nasdaq's Shareholders Equity Rule; Shares Rise
MT Newswires · 3d ago
NLS Pharmaceutics CEO Issues Letter To Shareholders
Benzinga · 12/22/2022 13:33
BRIEF-NLS Pharmaceutics Ltd Files Prospectus To The Resale, From Time To Time, By The Selling Shareholders Of Up To 11.9 Mln Common Shares - SEC Filing
Reuters · 12/06/2022 22:22
NLS Pharmaceutics Announces Launch Of Paid For Named Patient Program With Mazindol ER For Idiopathic Hypersomnia, A Serious Sleep Disorder With No Approved Treatment Options In Europe
Benzinga · 11/23/2022 13:34
U.S. FDA Grants Orphan Drug Designation (ODD) for Quilience(R) (Mazindol ER) for the Treatment of Idiopathic Hypersomnia (IH)
NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, ann...
ACCESSWIRE · 11/02/2022 14:40
NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development
NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, ann...
ACCESSWIRE · 09/08/2022 12:00
NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
NLS Pharmaceutics Ltd. (Nasdaq:NLSP), (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disor...
ACCESSWIRE · 07/28/2022 12:30
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
NLS Pharmaceutics Ltd.(NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorder...
ACCESSWIRE · 07/21/2022 12:30
More
About NLSPW
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.

Webull offers kinds of NLS Pharmaceutics AG stock information, including NASDAQ:NLSPW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NLSPW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NLSPW stock methods without spending real money on the virtual paper trading platform.